Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer
Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Glen Kristiansen(University Hospital Bonn), Stefan Hinz(Charité - Universitätsmedizin Berlin), Manfred Johannsen(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Manfred Dietel(Humboldt-Universität zu Berlin), Hans Krause(Charité - Universitätsmedizin Berlin), Holger Moch(University of Basel), Kurt Miller(Charité - Universitätsmedizin Berlin), Marc‐Oliver Riener, Steffen Weikert(St. Hedwig-Krankenhaus), Florian Fritzsche(University of Oxford)
Cited by 22
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996